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1. IntroductIon
In most humans, body weight is maintained in a stable 
condition. Humans can have the same body weight for 
many years, if the energy intake is equal to energy 
expenditure (energy balance). However, when the en-
ergy balance gets disturbed, this may lead to sustained 
weight problems, like in obese subjects.
In the developed and developing world, levels of 
obesity and its related disorders are increasing at a rate 
that could be considered of epidemic proportions. For 
this reason, the last years there is a significant increase 
in the knowledge of the physiological and molecular 
mechanisms regulating body mass1.
There are numerous peptides involved in the regu-
lation of energy homeostasis, some of which are pro-
duced centrally and others peripherally in the gastro-
intestinal tract, with some produced at both locations. 
These peptides have come to be known as members of 
the “gut-brain axis”. Interestingly, only one peripheral 
hormone, ghrelin, has been discovered that stimulates 
appetite, while many others inhibit appetite. As ghrelin 
effects on a large number of physiological functions, 
it may be involved in the pathomechanism of several 
human disorders, including disturbances of appetite, 
energy homeostasis and body weight.
The purpose of this review is to summarize the 
data about the role of ghrelin in the pathogenesis of 
human obesity. Thus the change levels of ghrelin and 
the identification of the molecular mechanisms me-
diating ghrelin effects on feeding, may provide new 
therapeutic targets for obesity.
2. the hormone ghrelIn
2a. What is ghrelin?
Ghrelin, a peptide hormone, was first described by 
Japanese researches in the journal Nature in Decem-
ber 19992. They chose the name “ghrelin” because 
“ghre” is the Proto-Indo-European root of the word 
“grow”, and ghrelin also stimulates the pituitary gland 
to release growth hormone. The majority of circulat-
ing ghrelin is released from the endocrine cells of the 
stomach mucosa (these cells have been identified as 
the X/A cells)3.
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It was discovered as part of a study to identify 
the previously unknown endogenous ligand for the 
growth hormone secretatogue receptor (GHS-R). It 
was known that this receptor was stimulated by syn-
thetic growth hormone-releasing compounds3.
Ghrelin is synthesized as a preprohormone (117-
amino-acid peptide), then proteolytically processed to 
yield a 28-amino acid peptide. An insteresting modifi-
cation is imposed on the hormone during synthesis in 
the form of an n-octanoic acid bound to one of its ami-
no acids (acyl ghrelin, called “simply ghrelin”)4. This 
modification is necessary for biologic activity. Ghrelin 
has a unique acid chain on its N-terminal end. 
However, the majority of circulating ghrelin is ac-
tually lacking this acyl group and is known as des-acyl 
or des-octanoyl ghrelin (> 90%). This may due to the 
sorter half-life of ghrelin than that of des-acyl ghrelin 
(it binds to the CHS-R in the tissues). Deacylation of 
ghrelin to des-acyl ghrelin is also responsible for the 
reduced half-life of ghrelin5. 
Recent developments have shown that ghrelin 
gene can generate various bioactive molecules besides 
ghrelin. These moleculs can be classified in three main 
groups: ghrelin and analogs, C-ghrelin and obestatin. 
All molecular forms of ghrelin were found in human 
plasma as well as in the stomach, but major active 
forms see to be acyl ghrelin and des-acyl ghrelin6. 
Ghrelin peptide was originally isolated from the 
stomach, but ghrelin protein has also been identified 
at lower levels in other tissues, such as the gastrointes-
tinal tract7, pancreas8, adrenal cortex9, ovary, plecen-
ta, fallopian tube, testis, prostate, liver, gall bladder, 
breast, thyroid, spleen, human lemphocytes, lung, kid-
ney, skeletal muscle, myocardium, vein and skin10,11. 
Ghrelin produced in tissues other than gastrointestinal 
tissues may have a range of still-unidentified physi-
ological autocrine or paracrine effects (GHS-R1a ex-
pression is also didected in many of these tissues).
In the brain, ghrelin-producing neurons have been 
identified in the pituitary, in the hypothalamic arcu-
ate nucleus (ARC) and in a group of neurons near to 
the third ventricle, between the dorsal, ventral, para-
ventricular and arcuate hypothalamic nuclei12,13,14. 
These neurons terminate on Neuropeptide Y (NPY), 
Agouti-related protein (AgRP), Proopiomelanocor-
tin (POMC) and Corticotrophin-relasing hormone 
(CHRH) neurons, forming a circuit which could me-
diate in energy homeostasis. Recently, Sato et al.15 
characterized ghrelin within the rat hypothalamus. 
The physiological role(s) of ghrelin secreted from the 
hypothalamus, however, remains unclear.
2b. Secretion and regulation of ghrelin levels
The secretion of ghrelin by the stomach depends 
largely on the nutrition state. Ghrelin levels show pre-
prandial increases and postprandial decreases16. In ad-
dition, ghrelin levels show a diurnal variation17 that is 
influenced by various factors (age, gender, body mass 
index, growth hormone, glucose and insulin17,18,19 (see 
Table 1)20.
Furthermore, leptin influence the circulate ghrelin 
levels. It has been suggested that the satiety-inducing 
effects of leptin suppress the secretion of ghrelin21.
Circulating ghrelin levels are increased by fast-
table 1. Regulators of circulating Ghrelin.
Effect on circulating Ghrelin
Food intake ↓
Age ↓ With increasing age
Gender Higher in females comparedto males
BMI ↓ With increasing BMI
GH ↓
Glucose ↓
Insulin ↓
BMI: Body Mass Index     GH: Growth Hormone
(From Klok MD et al 2006)
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ing and energy restriction and decreased by food 
intake22,16,23. In fact, circulating ghrelin levels are in-
creased in anorexia and cachexia, reduced in obesity 
and restored by weight recovery* 16. These changes 
are opposite to those of leptin and it has been sug-
gested that these hormones signal the metabolic bal-
ance and manage the neuroendocrine and metabolic 
response to starvation24,25. 
Insulin also has a temporal relationship with ghre-
lin concentrations. Insulin levels rise, as ghrelin levels 
fall.
Free fatty acids are suggested to reduse ghrelin lev-
els in human26 as well as glucagon, that reduce ghrelin 
levels by a pituitary-dependent mechanism27,28. 
Secretion of ghrelin in the hypothalamus is highly 
regulated by nutritional status sush as feeding, fasting 
and exposure to a high fat diet. Recent studies show 
that the metabolism of hypothalamic fatty acid medi-
ates the orexigenic action of ghrelin29. In the context 
of food deprivation, the increased ghrelin levels pro-
motes feeding through AMP-dependent protein kinase 
which mediate to the modulation of hypothalamic fat-
ty acid metabolism.
2c. Receptors
The effects of ghrelin are mediated via the growth 
hormone secretagogue receptors (GHSR) that are ex-
pressed by neurons in the arcuate nucleus and the ven-
tromedial hypothalamus.
The ghrelin receptor was known before ghrelin 
was discovered. It was named growth hormone secre-
tagogue receptor (GHS-R) because, when is activated 
potently, stimulates secretion of growth hormone. The 
natural ligand for the GHS-R was announced as ghre-
lin. 
The ghrelin receptor is a G protein-coupled re-
ceptor, with two variants that are designated, type 1a 
(GHS-R1a) and type 1b (GHS-R1b)11. GHS-R1a is 
highly expressed in the hypothalamus, the pituitary32 
and also in other areas of the CNS33. The role of GHS-
R1a is to control appetite, food intake and energy bal-
ance. Recent experiments showed that GHS-R1a is 
essential for the stimulatory effects of ghrelin on GH 
secretion, as well as its orexigenic effects34. Addition-
ally, they show that the acylation of ghrelin at Ser3 is 
necessary for GHSR activation35 and for crossing of 
the ghrelin the blood-brain barrier36.
So, des-acyl ghrelin does not bind GHS-R1a and 
its effects should be mediated by other receptors, spe-
cific for des-acyl ghrelin, or by receptors common to 
acyl and des-acyl ghrelin (non of this have been char-
acterized yet).
2d. How ghrelin exerts its effects
The peripheral ghrelin is released from the gastroin-
destinal tract (GI) and it is believed that it is come into 
the brain through three mechanisms (Figure 1)37:
a) directly, via the blood stream, to enter the anterior 
pituitary and other areas of the brain not protected 
by the blood brain barrier (BBB)38. 
b) directly by crossing the BBB.
c) indirectly, via the vagus nerve39. 
Ghrelin acts in the arcuate nucleus, a very impor-
tant area in the regulation of feeding and appetite38,40 
and also causes neuronal activity in the paraventricu-
lar nucleus, the lateral and dorsomedial hypothalamus, 
the area postrema, and in the nucleus of solitary tract.
In the ARC nucleus are found GHS receptors, on 
neurons that release NPY and AgRP peptides (po-
tent stimulators of weight gain)41, where ghrelin acts. 
GHS-R can be found on presynaptic nerve endings 
*  Orexigenic actions of ghrelin are extremely rapid and 
short-lived, as required for a signal influencing individual 
meal�related behavior44,45 . 
Figure 1. Ghrelin reaches the hypothalamus via three dif-
ferent pathways. (From Korbonits M, et al 2004).
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and influence the release of the transmitter. As well 
the researchers found, ghrelin promotes appetite in 
two ways (Figure 2)42: 
a) directly, by depolarizing the orexigenic neurons 
NPY/AgRP.
b) indirectly, by increasing the tonic inhibition, ex-
erted by the NPY/AgRP neurons over the anorexi-
genic POMC/CART (cocain-amphetamine related 
transcript) neurons.
2e. Effects of ghrelin
Ghrelin was identified via its growth-hormone releas-
ing effect. In addition to this effect, ghrelin exerts a 
wide spectrum of endocrine and nonendocrine ac-
tions, as: orexigenic effect, coupled with control of 
energy expenditure, control of gastric motility and 
acid secretion, influence on both endocrine and exo-
crine pancreatic function and on glucose metabolism, 
stimulation of lactotroph and corticotroph secretion, 
inhibition of gonadal axis, cardiovascular actions, in-
fluence on behavior and sleep, on bone physiology43 
modulation of cell proliferation and apoptosis.
Ghrelin, as an orexigenic factor* was considered 
triggering meal initiation, but it is not yet clear wheth-
er it is directly related to the rise in ghrelin levels46. As 
Theande-Carrillo et al.47 suggested that the well known 
pre-meal peaks of circulating ghrelin are triggering 
preparation processes in the CNS rather than actually 
initiating meals. Moreover, Sat et al.48 indicated that 
ghrelin is not critical for feeding performance.
The primary effect of ghrelin injections on meal 
patterns is to decrease the latency to feed. Thus ghrelin 
increase meal number without affecting meal size49. 
Ghrelin stimulates also gastrointestinal motility, gas-
tric acid secretion and pancreatic exocrine secretion. 
All these functions prepare the gastrointestinal tract 
for effective trasport and processing of food. Ghrelin 
administration increases also the enzyme activity of 
numerous lysosomal hydrolases50, possibly helping 
the body prepare to digest nutrients. Ghrelin also in-
creases RQ in obese humans. This suggests that this 
protein regulates substrate utilization and may pro-
mote metabolic flexibility51.
The peripheral ghrelin signal the status of energy 
balance to the central nervous system52 and promotes 
food intake through the activation of the hypothalamic 
orexin neurons, neuropeptide Y-Y1 receptor pathway 
and over-expressing the agouti-related protein53.
In addition to those effects, ghrelin has been also 
implicated on the regulation of lipid metabolism, with 
effects in the liver, skeletal muscle and adipose tissue. 
Ghrelin stimulates lipogenesis in differentiated adipo-
cytes in vitro and in vivo, by increasing the levels of 
peroxisome proliferator-activated receptor a and the 
insulin-induced glucose uptake54. Also ghrelin antag-
onizes lipolysis55 reducing isoproterenol-stimulated 
lipolysis in vitro56 and stimulates the proliferation and 
differentiation of preadipocytes.
The central ghrelin and NPY mRNA levels are sig-
nificantly higher in the hypothalamus in obese com-
pared to lean subjects57. This suggests an important 
role for a central ghrelin in the pathogenesis of obesity 
in humans.
3. ghrelIn And oBeSIty
It is still not clear if abnormalities in ghrelin system 
is the cause or a consequense of obesity. In obese 
humans circulating ghrelin levels are negatively cor-
related with percentage body fat and BMI23 and are 
therefore lower in obese subjects than in normal body 
Figure 2. Ghrelin effect on appetite control. (From Flier SJ 
& Maratos-Flier E. Scientific American 2007).
*  Animal studies suggest that weight reduction causes a 
rise in circulating ghrelin levels, an increase in ghrelin re�
ceptor expression in the hypothalamus30, as well as sensitiv�
ity to the orexigenic actions of ghrelin 31.
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weight controls. Obese humans show also, a disturbed 
diurnal variation in ghrelin levels21. 
Ghrelin is linked to obesity in two ways:
a) through its short-term (day to day, meal to meal) 
effects on hunger and meal initiation.
b) through its long-term (year to year) control of en-
ergy balance. 
In essence ghrelin makes people eat more than they 
need to and makes them store calories as fat. Ghre-
lin makes also very difficult to maintain diet-indused 
weight loss, because its levels show an increase, as if 
to compensate for this weight loss58. 
It is thought that ghrelin is linked to excessive food 
intake in two ways:
a) the postprandial reduction* in ghrelin levels may 
increase the time for which the subject feels hun-
gry. 
b) the elevated ghrelin levels may not reduced the 
speed of gastric emptying59 and the feeling of sa-
tiety not elicited. So, without the feeling of satiety 
obese humans eat more than they need and thus 
gain weight. 
Furthermore, in obesity, the lower ghrelin levels 
may increase the use of fats as a metabolic fuel60. 
Actually, Tschöp et al.44 found that ghrelin regulates 
the body’s choise of metabolic substrate44. Actually, 
recent studies show that the orexigenic action of ghre-
lin, results from the fatty acid metabolism in hypo-
thalamus29. However, as body weight is reduced, the 
ghrelin levels are increased, reducing the use of fat as 
metabolic fuel and more fat is conserved and stored*.
Obese humans do not lose their responsiveness to 
ghrelin, but may be are oversensitive to this, for ex-
ample, because of an overexpression of the GHS-R. 
In fact, it has been shown that a low-dose infusion of 
ghrelin increased the energy intake in obese people 
and not in lean people61. In addition, a high-dose in-
fusion with ghrelin led to a higher increase in food 
intake in obese patients compared with lean subjects.
Many studies have been performed to investigate 
ghrelin as therapeutic target for obesity treatment. In 
a study with rats it was demonstrated that anti-ghrelin 
blocks ghrelin-induced increase in food intake after 
ghrelin injection62. 
In addition, the ghrelin receptor is another poten-
cial drug target. It has been demonstrated that GHS-R 
antagonists result in a decrease of energy intake in 
lean and obese mice63. However, as it is possible, the 
ghrelin system functions differently in humans, more 
research is still necessary.
One other strategy is to target genes that are in-
volved in ghrelin functioning. That is the use of agents 
that stimulate inhibitors of ghrelin signaling, in order 
to suppress ghrelin’s stimulatory effect on food intake 
and body weight.
Furthermore, the peptide ghrelin constitute pos-
sible target for therapeutic intervention. Makimura et 
al.64 demonstrated that a reduction of hypothalamic 
AgRP results in an increase of metabolic rate and a 
decrease of body weight, without affecting food in-
take in mice. This suggests that agents antagonizing 
the effect of AgRP may be a useful strategy to treat 
obesity64.
The researches also suggest, that the size, the com-
position* of a meal and the frequency of meals have 
Figure 3. Average plasma Ghrelin concentrations during 
the course of a day. 
(From Cummings DE, et al Diabetes 2001).
*  In human subjects, plasma ghrelin levels increase nearly 
two fold immediatly before meals and fall within 1h after 
eating16.
*  Intact b�adrenergic signaling is required for the ghrelin�
indused increase in body weight gain47. In human subjects, 
plasma ghrelin levels increase nearly two fold immediatly 
before meals and fall within 1h after eating16. (See Figure 
3).
* Lipids suppress ghrelin levels less effectively than carbo�
hydrates or proteins do65,66.
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significant effects on ghrelin levels and concequently 
on development of obesity67,68,69. It is important for 
obese humans to follow a specific diet in order to reg-
ulate food intake and body weight. 
4. concluSIon
Since its discovery in 1999, ghrelin has become one 
of the most important subjects of scientific research. 
This is due to the multiple functions of ghrelin actions 
such as the metabolic effects and various others, in-
cluding the cardiovascular, endocrine and immuno-
logical ones.
Ghrelin is believed that it is involved in sort-term 
and long-term regulation of energy balance, control 
of appetite, selection of metabolic substrates, stimula-
tion of gastric acid secretion and regulation of gastro-
intestinal tract motility. It produces these effects in the 
hypothalamus, directly through activating the AgRP/
NPY neurons and also indirectly through inhibiting 
the POMC/CART neurons.
The functions and the effects of ghrelin have been 
well documented, but the mechanisms that regulate its 
release are less well understood.
Ghrelin is linked to obesity, because makes people 
to eat more than they need, to store excess calories 
as fat and to make difficult to maintain diet-induced 
weight loss. So, increasing the possibility that block-
ade of ghrelin action (with ghrelin-receptor antago-
nists) might promote weight loss in obese individuals. 
Furthermore, ghrelin antagonists may, in future, have 
a powerful role to play in the medical management of 
obesity. However, Lu et al.70 have been reported that 
antagonizing the peripheral ghrelin pathway alone, 
may not be effective for treating obesity. Combina-
tion therapies that block multiple orexigenic pathways 
may be needed to evaluate the anti-ghrelin therapies.
ΠΕΡΙΛΗΨΗ: Η γκρελίνη, μία ορμόνη που ανακαλύφθηκε τελευταία, εντοπίσθηκε αρχικά στον στόμαχο, παρόλο που 
υπάρχει και σε άλλες περιοχές του σώματος. Οι επιστήμονες, ερευνώντας τα επίπεδα της γκρελίνης διαπίστωσαν ότι, όταν 
είναι αυξημένη η στάθμη της στον οργανισμό, είναι αυξημένο και το αίσθημα της πείνας. Επιπλέον βρέθηκε ότι, υψηλές 
στάθμες γκρελίνης καταστέλλουν το καταναλισκόμενο ποσό λίπους του λιπώδους ιστού. 
Στον άνθρωπο η γκρελίνη παίζει ρόλο στη ρύθμιση της ενεργειακής ισορροπίας και στην αύξηση του οργανισμού. Όμως, 
όταν διαταράσσεται η ενεργειακή ισορροπία (προσλαμβανόμενη ενέργεια > καταναλισκόμενη ενέργεια), προκύπτουν προ-
βλήματα στη διατήρηση του βάρους, όπως π.χ. στους παχύσαρκους.
Παχυσαρκία είναι η υπερβολική συγκέντρωση λίπους στο σώμα. Η κατάσταση αυτή αποτέλεσε διεθνές πρόβλημα υγείας, 
για το οποίο, οι δυνατότητες για δραστική θεραπεία, είναι περιορισμένες.
Στην παρούσα ανασκόπηση συνοψίζονται τα διαθέσιμα στοιχεία που αφορούν την ορμόνη γκρελίνη. Σύμφωνα με τα στοιχεία 
αυτά, η γκρελίνη, ως αναβολική ορμόνη, συμμετέχει στη ρύθμιση της ενεργειακής ισορροπίας, της πρόσληψης της τροφής 
και της ρύθμισης του σωματικού βάρους. Επειδή δε τα επίπεδά της μεταβάλλονται έντονα στα παχύσαρκα άτομα, σημαίνει 
ότι ο ρόλος της ορμόνης αυτής είναι σημαντικός σε ότι αφορά την παχυσαρκία.
Λέξεις Kλειδιά: Γκρελίνη, Ρύθμιση σωματικού βάρους, Παχυσαρκία.
Γκρελίνη: οι στάθμες της γκρελίνης έχουν σχέση με την παχυσαρκία;
Αναστασία Καΐκη-Αστάρα
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